CA2588966C - Cladribine regimen for treating multiple sclerosis - Google Patents

Cladribine regimen for treating multiple sclerosis Download PDF

Info

Publication number
CA2588966C
CA2588966C CA2588966A CA2588966A CA2588966C CA 2588966 C CA2588966 C CA 2588966C CA 2588966 A CA2588966 A CA 2588966A CA 2588966 A CA2588966 A CA 2588966A CA 2588966 C CA2588966 C CA 2588966C
Authority
CA
Canada
Prior art keywords
cladribine
month
daily dose
consecutive days
beginning
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2588966A
Other languages
English (en)
French (fr)
Other versions
CA2588966A1 (en
Inventor
Giampiero De Luca
Arnaud Ythier
Alain Munafo
Maria Lopez-Bresnahan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Merck Serono SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36227798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2588966(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Serono SA filed Critical Merck Serono SA
Priority to CA3087419A priority Critical patent/CA3087419C/en
Publication of CA2588966A1 publication Critical patent/CA2588966A1/en
Application granted granted Critical
Publication of CA2588966C publication Critical patent/CA2588966C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA2588966A 2004-12-22 2005-12-20 Cladribine regimen for treating multiple sclerosis Expired - Lifetime CA2588966C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3087419A CA3087419C (en) 2004-12-22 2005-12-20 Cladribine regimen for treating multiple sclerosis

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US63866904P 2004-12-22 2004-12-22
US60/638,669 2004-12-22
EP04106909.7 2004-12-22
EP04106909 2004-12-22
PCT/EP2005/056954 WO2006067141A1 (en) 2004-12-22 2005-12-20 Cladribine regimen for treating multiple sclerosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3087419A Division CA3087419C (en) 2004-12-22 2005-12-20 Cladribine regimen for treating multiple sclerosis

Publications (2)

Publication Number Publication Date
CA2588966A1 CA2588966A1 (en) 2006-06-29
CA2588966C true CA2588966C (en) 2020-07-21

Family

ID=36227798

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2588966A Expired - Lifetime CA2588966C (en) 2004-12-22 2005-12-20 Cladribine regimen for treating multiple sclerosis
CA3087419A Expired - Lifetime CA3087419C (en) 2004-12-22 2005-12-20 Cladribine regimen for treating multiple sclerosis

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3087419A Expired - Lifetime CA3087419C (en) 2004-12-22 2005-12-20 Cladribine regimen for treating multiple sclerosis

Country Status (25)

Country Link
US (2) US7713947B2 (enExample)
EP (7) EP2805723B1 (enExample)
JP (7) JP5795456B2 (enExample)
KR (1) KR20070091662A (enExample)
AR (1) AR052830A1 (enExample)
AU (2) AU2005318190B2 (enExample)
BR (1) BRPI0517132B8 (enExample)
CA (2) CA2588966C (enExample)
CY (3) CY1112614T1 (enExample)
DK (3) DK2805723T3 (enExample)
EA (1) EA015799B1 (enExample)
ES (2) ES2921858T3 (enExample)
FI (1) FI4070800T3 (enExample)
FR (1) FR18C1008I2 (enExample)
HR (1) HRP20120228T1 (enExample)
HU (3) HUE070333T2 (enExample)
IL (2) IL183930A0 (enExample)
LT (3) LT3332789T (enExample)
LU (1) LUC00064I2 (enExample)
MX (1) MX2007007610A (enExample)
NO (1) NO20073813L (enExample)
PL (4) PL4070800T3 (enExample)
SG (1) SG160391A1 (enExample)
SI (3) SI2805723T1 (enExample)
WO (1) WO2006067141A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2805723T3 (da) 2004-12-22 2018-01-29 Merck Serono Sa Cladribin-regime til behandling af multipel sclerose
CA2649810A1 (en) * 2006-05-24 2007-11-29 Laboratoires Serono S.A. Cladribine regimen for treating multiple sclerosis
EP2343074A1 (en) 2009-12-23 2011-07-13 Merck Serono S.A. Use of purine analogues for treating airway diseases
WO2011117267A1 (en) 2010-03-24 2011-09-29 Merck Serono Sa Cladribine treatment of multiple sclerosis in patient groups defined by genotype
EP2428201A1 (en) 2010-09-08 2012-03-14 Merck Serono S.A. Oral administration of nucleoside monophosphates
WO2012097867A1 (en) 2011-01-18 2012-07-26 Synthon Bv Cladribine particles and pharmaceutical compositions comprising them
GB201401465D0 (en) * 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
GB2564717A (en) * 2017-07-21 2019-01-23 Chord Therapeutics S A R L Use of cladribine for treating autoimmune neuromuscular disease
KR20250005506A (ko) 2017-11-24 2025-01-09 메르크 파텐트 게엠베하 진행 형태의 다발성 경화증의 치료에서 사용을 위한 클라드리빈 용법
GB2601786A (en) 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1269659A (en) 1984-08-06 1990-05-29 Brigham Young University Method for the production of 2'-deoxyadenosine compounds
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US4964848A (en) * 1988-06-27 1990-10-23 Bloom Philip M Treatment of multiple sclerosis with lymphocytapheresis and chemo-immunosuppression
US5208327A (en) 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
US5641757A (en) 1994-12-21 1997-06-24 Ortho Pharmaceutical Corporation Stable 2-chloro-2'-deoxyadenosine formulations
CA2208484C (en) 1994-12-22 2008-09-23 Ortho Pharmaceutical Corporation Soluble 2-chloro-2'-deoxyadenosine formulations
US6194395B1 (en) 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
WO2000064918A1 (en) 1999-04-28 2000-11-02 Sterrenbeld Biotechnologie North America, Inc. METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE
DE10237146A1 (de) * 2002-08-13 2004-03-04 Medac Gesellschaft für klinische Spezialpräparate mbH Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose
JP4757632B2 (ja) 2002-09-25 2011-08-24 ブリガム ヤング ユニバーシティー ２’−デオキシグアノシンから２−クロロ−２’−デオキシアデノシンを調製する方法
GB2394658A (en) * 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
WO2004075903A1 (en) * 2003-02-25 2004-09-10 Applied Research Systems Ars Holding N.V. Combined use of ribavirin and interferon beta in demyelinating diseases
CA2520522C (en) 2003-03-28 2012-05-29 Ivax Corporation Cladribine formulations for improved oral and transmucosal delivery
US7888328B2 (en) 2003-03-28 2011-02-15 Ares Trading S.A. Oral formulations of cladribine
DK2805723T3 (da) 2004-12-22 2018-01-29 Merck Serono Sa Cladribin-regime til behandling af multipel sclerose
CA2649810A1 (en) * 2006-05-24 2007-11-29 Laboratoires Serono S.A. Cladribine regimen for treating multiple sclerosis

Also Published As

Publication number Publication date
CA3087419A1 (en) 2006-06-29
BRPI0517132B8 (pt) 2021-05-25
LTC2805723I2 (lt) 2022-04-25
EP4523753A2 (en) 2025-03-19
DK2805723T3 (da) 2018-01-29
JP2008524313A (ja) 2008-07-10
PL4070800T3 (pl) 2025-03-10
IL212421A0 (en) 2011-06-30
CA2588966A1 (en) 2006-06-29
LUC00064I1 (enExample) 2018-02-14
CY1112614T1 (el) 2016-02-10
JP2018165271A (ja) 2018-10-25
EP1827461A1 (en) 2007-09-05
ES3007339T3 (en) 2025-03-19
LTPA2018503I1 (lt) 2018-03-12
EP4070800A1 (en) 2022-10-12
JP2017101061A (ja) 2017-06-08
EA015799B1 (ru) 2011-12-30
PL3332789T3 (pl) 2022-08-22
EP1827461B1 (en) 2012-02-29
US20090081163A1 (en) 2009-03-26
EA200701221A1 (ru) 2008-02-28
JP2020193206A (ja) 2020-12-03
IL183930A0 (en) 2007-10-31
NO20073813L (no) 2007-09-21
JP6430554B2 (ja) 2018-11-28
US20100203017A1 (en) 2010-08-12
CA3087419C (en) 2023-03-07
HRP20120228T1 (hr) 2012-04-30
EP2805723B1 (en) 2018-01-17
EP3332789B1 (en) 2022-04-06
CY2018006I1 (el) 2018-06-27
HUS1800009I1 (hu) 2018-05-02
DK3332789T3 (da) 2022-07-11
DK4070800T3 (da) 2025-01-02
ES2921858T3 (es) 2022-09-01
JP5795456B2 (ja) 2015-10-14
CY2018006I2 (el) 2018-06-27
PL1827461T3 (pl) 2012-07-31
FR18C1008I2 (fr) 2019-03-01
JP6092945B2 (ja) 2017-03-08
JP5908863B2 (ja) 2016-04-26
AR052830A1 (es) 2007-04-04
EP3332789A1 (en) 2018-06-13
BRPI0517132A (pt) 2008-09-30
EP2263678B1 (en) 2014-06-11
EP4523753A3 (en) 2025-05-28
EP2275110A3 (en) 2011-04-27
AU2011200768B2 (en) 2012-09-13
IL212421A (en) 2014-01-30
LT4070800T (lt) 2025-01-10
LT3332789T (lt) 2022-07-25
SI2805723T1 (en) 2018-02-28
LUC00064I2 (enExample) 2018-03-28
FR18C1008I1 (enExample) 2018-03-30
SI3332789T1 (sl) 2022-08-31
JP2016138128A (ja) 2016-08-04
JP2015180685A (ja) 2015-10-15
EP4070800B1 (en) 2024-10-16
EP2275110A2 (en) 2011-01-19
WO2006067141A1 (en) 2006-06-29
EP2805723A1 (en) 2014-11-26
AU2005318190A1 (en) 2006-06-29
HUE059133T2 (hu) 2022-10-28
CY1119790T1 (el) 2018-06-27
EP2263678A3 (en) 2011-04-27
AU2011200768A1 (en) 2011-03-17
KR20070091662A (ko) 2007-09-11
US7713947B2 (en) 2010-05-11
EP2275110B1 (en) 2013-07-10
JP6290962B2 (ja) 2018-03-07
SI4070800T1 (sl) 2025-03-31
JP2013216664A (ja) 2013-10-24
AU2005318190B2 (en) 2010-11-25
MX2007007610A (es) 2007-08-03
FI4070800T3 (fi) 2025-01-14
PL2805723T3 (pl) 2018-04-30
SG160391A1 (en) 2010-04-29
BRPI0517132B1 (pt) 2020-02-18
US8377903B2 (en) 2013-02-19
HUE070333T2 (hu) 2025-05-28
EP2263678A2 (en) 2010-12-22

Similar Documents

Publication Publication Date Title
AU2011200768B2 (en) Cladribine regimen for treating multiple sclerosis
HK40083827A (en) Cladribine regimen for treating multiple sclerosis
HK40083827B (en) Cladribine regimen for treating multiple sclerosis
ES2382554T3 (es) Pauta posológica de cladribina para el tratamiento de la esclerosis múltiple
CN101090726A (zh) 治疗多发性硬化的克拉屈滨方案
HK1110517A (en) Cladribine regimen for treating multiple sclerosis

Legal Events

Date Code Title Description
EEER Examination request